Nom du produit:1-(3-fluoro-4-methoxypyridin-2-yl)methanamine hydrochloride

IUPAC Name:1-(3-fluoro-4-methoxypyridin-2-yl)methanamine hydrochloride

CAS:1933516-25-6
Formule moléculaire:C7H10ClFN2O
Pureté:95%+
Numéro de catalogue:CM1045609
Poids moléculaire:192.62

Unité d'emballage Stock disponible Prix($) Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:1933516-25-6
Formule moléculaire:C7H10ClFN2O
Point de fusion:-
Code SMILES:Cl.COC1=C(F)C(CN)=NC=C1
Densité:
Numéro de catalogue:CM1045609
Poids moléculaire:192.62
Point d'ébullition:
N° Mdl:
Stockage:

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Sebetralstat
KalVista Pharmaceuticals recently announces Phase 3 KONFIDENT trial of Sebetralstat meets all primary and key secondary endpoints as first oral on-demand therapy for Hereditary Angioedema (HAE). HAE is a rare and potentially life-threatening genetic disease caused by low levels or dysfunction of the C1 inhibitor, associated with uncontrolled plasma kallikrein (PKa) activity and generation of bradykinin (BK).
Sebetralstat is an investigational novel, oral plasma kallikrein inhibitor with a favorable safety profile. It works by targeting the kallikrein–kinin system (KKS), reducing the activity of plasma kallikrein and blocking uncontrolled bradykinin release in HAE attack. The Phase 3 results also show rapid symptom relief in a broad HAE population.